AtriCure Newsroom

A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $36 to $60

Moomoo NewsOct 31 09:21 ET

AtriCure Is Maintained at Overweight by JP Morgan

Dow JonesOct 30 11:30 ET

UBS Maintains Buy on AtriCure, Raises Price Target to $40

BenzingaOct 30 09:35 ET

A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $36 to $60

Moomoo NewsOct 30 09:13 ET

AtriCure Analyst Ratings

BenzingaOct 30 06:57 ET

CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $49

Moomoo NewsAug 14 07:35 ET

Atricure's Market Strength and Innovation Justify Buy Rating

TipRanksAug 14 07:25 ET

Oppenheimer Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $32

Moomoo NewsAug 1 00:31 ET

Navigating 6 Analyst Ratings For AtriCure

BenzingaJul 31 15:02 ET

AtriCure Price Target Cut to $53.00/Share From $58.00 by BTIG

Dow JonesJul 31 14:55 ET

JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30

BenzingaJul 31 14:33 ET

A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $26 to $60

Moomoo NewsJul 31 09:18 ET

AtriCure Price Target Cut to $40.00/Share From $65.00 by Piper Sandler

Dow JonesJul 31 08:06 ET

AtriCure Analyst Ratings

BenzingaJul 31 07:55 ET

Piper Sandler Remains a Buy on Atricure (ATRC)

TipRanksJul 31 06:58 ET

Analysts Are Bullish on These Healthcare Stocks: Incyte (INCY), Atricure (ATRC)

TipRanksJul 31 06:57 ET

AtriCure's Growth Prospects and Buy Rating Despite Short-Term Challenges

TipRanksJul 31 00:54 ET

Analyst Ratings For AtriCure

BenzingaJul 8 15:02 ET

AtriCure Analyst Ratings

BenzingaJul 8 14:01 ET

Atricure's Competitive Landscape Clears: A Buy Rating Amid Delayed Threats and Growth Prospects

TipRanksJul 8 13:17 ET